Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind comparison of HLX11 versus EU-Perjeta in neoadjuvant treatment of HER2-positive, hormone receptor-negative breast cancer
CTR20220391Phase 3Completed
- Sponsor
- HyBioPharma
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pertuzumab in breast cancer, sponsored by HyBioPharma. Started Apr 2022; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20220391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220391.